AAP
NRIX icon

Arax Advisory Partners’s Nurix Therapeutics NRIX Stock Holding History

Arax Advisory Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
+722
New +$12.3K ﹤0.01% 4050
2026
Q1 		– Sell
-44
Closed -$836 – 4165
2025
Q4 		$836 Sell
44
-69
-61% -$991 ﹤0.01% 3525
2025
Q3 		$1.04K Buy
+113
New +$1.17K ﹤0.01% 3249
2025
Q1 		– Sell
-130
Closed -$2.45K – 2925
2024
Q4 		$2.45K Hold
130
– – ﹤0.01% 1961
2024
Q3 		$2.92K Hold
130
– – ﹤0.01% 1919
2024
Q2 		$2.71K Buy
+130
New +$2.02K ﹤0.01% 1854

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's NRIX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 722 shares worth $17.5K. The stake represents ﹤0.01% of the portfolio and ranks #4050 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in NRIX as recently as Q4 2025.

Arax Advisory Partners first reported a position in NRIX in Q2 2024 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Arax Advisory Partners held 722 shares of Nurix Therapeutics worth $17.5K as of Q2 2026.
  • Nurix Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4050 holding.
  • Arax Advisory Partners first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.